MSS型mCRC的免疫治疗策略及中医药研究探索  

Immunotherapy strategies and traditional Chinese medicine treatment for microsatellite stable metastatic colorectal cancer

作　　者：江雨静 郭乃婷 夏雪萍 季漪 霍介格[2] Yu-Jing Jiang;Nai-Ting Guo;Xue-Ping Xia;Yi Ji;Jie-Ge Huo(The Third Clinical Medical College of Nanjing University of Chinese Medicine,Nanjing 210028,Jiangsu Province,China;Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing 210028,Jiangsu Province,China)

机构地区：[1]南京中医药大学第三临床医学院,江苏省南京市210028 [2]南京中医药大学附属中西医结合医院,江苏省南京市210028

出　　处：《世界华人消化杂志》2023年第24期1007-1013,共7页World Chinese Journal of Digestology

基　　金：国家自然科学基金,No.82004288;国家中医药管理局第七批全国老中医药专家学术经验继承工作,国中医药人教[2022]76号;江苏省卫健委医学科研重点项目,No.ZD2022020;江苏省中医消化肿瘤临床医学创新中心,苏中医科教[2021]6号.

摘　　要：结直肠癌(colorectal cancer,CRC)发病率和死亡率逐年上升,除传统的放疗、化疗、靶向治疗模式外,免疫治疗也为更多转移性结直肠癌患者带来希望,但这仅限于对高微卫星不稳定型的患者,对约占95%的微卫星稳定(microsatellite stable,MSS)型的转移性结直肠癌(metastatic colorectal cancer,mCRC)患者尚不能从中获益,如何增强MSS型mCRC患者对免疫治疗的应答是当前研究的热点.近年来研究发现免疫治疗的联合策略有望改善此类患者的临床疗效,中医药联合免疫治疗的研究报道日趋增多.因此,本文旨在对MSS型结直肠癌的免疫治疗和中医药研究进行综述.The incidence and mortality of colorectal cancer(CRC)have increased year by year.In addition to traditional radiotherapy,chemotherapy,and targeted therapy,immunotherapy also brings hope to more patients with metastatic colorectal cancer(mCRC).However,these treatments are limited to patients with high microsatellite instability,and about 95%of mCRC patients with microsatellite stability(MSS)can not benefit from them.How to enhance the response of MSS mCRC patients to immunotherapy is the focus of current research.In recent years,it has been found that immunotherapy strategies are expected to improve the clinical efficacy for such patients,and the research reports of TCM combined with immunotherapy are increasing day by day.Therefore,this article aims to review the immunotherapy and traditional Chinese medicine treatment for MSS colorectal cancer.

关 键 词：结直肠癌 微卫星稳定 免疫治疗 中医药 

分 类 号：R735.3[医药卫生—肿瘤]